Faecal Microbiota Transfer – a new concept for treating cytomegalovirus colitis in children with 
ulcerative colitis

Karolewska-Bochenek, Katarzyna; Łazowska-Przeorek, Izabella; Grzesiowski, Paweł; Dziekiewicz, Marcin; Dembiński, Łukasz; Albrecht, Piotr; Radzikowski, Andrzej; Banaszkiewicz, Aleksandra

doi:10.26444/aaem/118189

Cited by 8 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Forest plot displaying the pooled rate of adverse events of FMT among IBD patients. References: Nicholson et al, 2022 [ 32 ]; Karolewska-Bochenek et al, 2021 [ 36 ]; Nicholson et al, 2020 [ 33 ]; Cho et al, 2019 [ 34 ]; Shimizu et al, 2019 [ 42 ]; Karolewska-Bochenek et al, 2018 [ 37 ]; Goyal et al, 2018 [ 38 ]; Fareed et al, 2018 [ 35 ]; Hourigan et al, 2015 [ 39 ]; Kunde et al, 2013 [ 41 ]; Suskind et al, 2015 [ 40 ]. …”

Section: Figurementioning

confidence: 99%

Safety and Efficacy of Fecal Microbiota Transplantation in Treatment of Inflammatory Bowel Disease in the Pediatric Population: A Systematic Review and Meta-Analysis

et al. 2023

View full text Add to dashboard Cite

Background and Aims: Fecal microbiota transplantation (FMT) has been increasingly studied in the inflammatory bowel disease (IBD) population. However, most studies have focused on the adult population, and the safety and efficacy of FMT in a pediatric population is less well understood. This systematic review and meta-analysis investigates the safety and efficacy of FMT in a pediatric IBD population. Methods: A comprehensive literature search of publications published prior to 30 June 2022 was undertaken. Safety data, IBD-related outcomes, and microbiome analysis were obtained from these studies when accessible. Individual estimates of each study were pooled, and sensitivity analysis was conducted. Results: Eleven studies satisfied our eligibility criteria. The calculated pooled rate of adverse events was 29% (95% confidence interval [CI]: 15.0%, 44.0%; p < 0.001; I2 = 89.0%, Q = 94.53), and the calculated pooled rate of serious adverse events was 10% (95% confidence interval [CI]: 6.0%, 14.0%; p = 0.28; I2 = 18.0%, Q = 9.79). One month after FMT, clinical response was achieved in 20/34 (58.8%) pediatric IBD patients, clinical remission was achieved in 22/34 (64.7%), and both clinical response and remission were achieved in 15/34 (44.1%) pediatric IBD patients. Conclusions: FMT can be a safe and effective treatment in the pediatric IBD population and may demonstrate improved safety and efficacy in the pediatric population compared to the adult population. However, our results are limited by a lack of established protocol as well as long-term follow-up for FMT in a pediatric IBD population.

show abstract

Section: Figurementioning

confidence: 99%

Safety and Efficacy of Fecal Microbiota Transplantation in Treatment of Inflammatory Bowel Disease in the Pediatric Population: A Systematic Review and Meta-Analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…[38] Other viral infections FMT appeared to be efficacious in norovirus infection and cytomegalovirus colitis. [39,40]…”

Section: Hepatitis Bmentioning

confidence: 99%

Encyclopedia of fecal microbiota transplantation: a review of effectiveness in the treatment of 85 diseases

Wang

Zhang

Borody

et al. 2022

Chinese Medical Journal

View full text Add to dashboard Cite

Fecal microbiota transplantation (FMT) has been used as a core therapy for treating dysbiosis-related diseases by remodeling gut microbiota. The methodology and technology for improving FMT are stepping forward, mainly including washed microbiota transplantation (WMT), colonic transendoscopic enteral tubing (TET) for microbiota delivery, and purified Firmicutes spores from fecal matter. To improve the understanding of the clinical applications of FMT, we performed a systematic literature review on FMT published from 2011 to 2021. Here, we provided an overview of the reported clinical benefits of FMT, the methodology of processing FMT, the strategy of using FMT, and the regulations on FMT from a global perspective. A total of 782 studies were included for the final analysis. The present review profiled the effectiveness from all clinical FMT uses in 85 specific diseases as eight categories, including infections, gut diseases, microbiota–gut–liver axis, microbiota–gut–brain axis, metabolic diseases, oncology, hematological diseases, and other diseases. Although many further controlled trials will be needed, the dramatic increasing reports have shown the promising future of FMT for dysbiosis-related diseases in the gut or beyond the gut.

show abstract

“…The children received FMT via nasogastric tube on five consecutive days every two weeks and were assessed for clinical remission after six weeks. Three out of eight children achieved clinical remission, and no adverse effects were recorded during or after the treatment [ 94 ]. Despite efficacy not being achieved in the majority of the patients, it still provided a new and promising therapeutic option for CMV colitis.…”

Section: Fecal Microbiota Transplantation In Human Diseasesmentioning

confidence: 99%

Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases

Biazzo

Deidda

2022

JCM

View full text Add to dashboard Cite

The human body is home to a variety of micro-organisms. Most of these microbial communities reside in the gut and are referred to as gut microbiota. Over the last decades, compelling evidence showed that a number of human pathologies are associated with microbiota dysbiosis, thereby suggesting that the reinstatement of physiological microflora balance and composition might ameliorate the clinical symptoms. Among possible microbiota-targeted interventions, pre/pro-biotics supplementations were shown to provide effective results, but the main limitation remains in the limited microbial species available as probiotics. Differently, fecal microbiota transplantation involves the transplantation of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient’s gut microbial composition aiming to confer a health benefit. Firstly used in the 4th century in traditional Chinese medicine, nowadays, it has been exploited so far to treat recurrent Clostridioides difficile infections, but accumulating data coming from a number of clinical trials clearly indicate that fecal microbiota transplantation may also carry the therapeutic potential for a number of other conditions ranging from gastrointestinal to liver diseases, from cancer to inflammatory, infectious, autoimmune diseases and brain disorders, obesity, and metabolic syndrome. In this review, we will summarize the commonly used preparation and delivery methods, comprehensively review the evidence obtained in clinical trials in different human conditions and discuss the variability in the results and the pivotal importance of donor selection. The final aim is to stimulate discussion and open new therapeutic perspectives among experts in the use of fecal microbiota transplantation not only in Clostridioides difficile infection but as one of the first strategies to be used to ameliorate a number of human conditions.

show abstract

Faecal Microbiota Transfer – a new concept for treating cytomegalovirus colitis in children with ulcerative colitis

Abstract: Transfer-a new concept for treating cytomegalovirus colitis in children with ulcerative colitis. Ann Agric Environ Med.

Cited by 8 publications

References 25 publications

Safety and Efficacy of Fecal Microbiota Transplantation in Treatment of Inflammatory Bowel Disease in the Pediatric Population: A Systematic Review and Meta-Analysis

Safety and Efficacy of Fecal Microbiota Transplantation in Treatment of Inflammatory Bowel Disease in the Pediatric Population: A Systematic Review and Meta-Analysis

Encyclopedia of fecal microbiota transplantation: a review of effectiveness in the treatment of 85 diseases

Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases

Contact Info

Product

Resources

About